New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 25, 2014
11:07 EDTBIIBBiogen reports British Columbia to Reimburse TECFIDERA
Biogen Idec Canada announced that TECFIDERA is now available for reimbursement in British Columbia through B.C. PharmaCare. Effective June 24, TECFIDERA is now eligible for reimbursement as a first-line monotherapy for people diagnosed with RRMS according to the current McDonald clinical criteria and magnetic resonance imaging evidence, when prescribed by a neurologist from a designated MS clinic, who meet the following criteria: is 18 years of age or older; meet the Limited Coverage criteria; has had at least two disabling attacks of MS in the previous two years; and is ambulatory with or without aid with an Expanded Disability Status Scale score of 6.5 or less. TECFIDERA is also available as a second-line monotherapy for a change of therapy, when prescribed by a neurologist from a designated MS clinic, for the treatment of patients with relapsing-remitting MS who have experienced failure or intolerance to a previous disease-modifying therapy.
News For BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 25, 2014
11:08 EDTBIIBBiogen to add PML info on Tecfidera label after patient dies
Subscribe for More Information
11:04 EDTBIIBFDA says Biogen adding PML information on Tecfidera label
November 24, 2014
07:59 EDTBIIBBiogen resumed with an Outperform at Leerink
Subscribe for More Information
November 19, 2014
07:52 EDTBIIBInforma Business Information to hold a conference
Subscribe for More Information
07:21 EDTBIIBBiogen price target lowered to $400 from $425 at Credit Suisse
Credit Suisse lowered Biogen's price target to $400 from $425 based on Gilenya PPMS risk but retains its Outperform rating based on the quality of earnings growth and pipeline.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use